Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) is on recovery track with 5.66% gain from a 1-year low price of $2.12. The company added 2.28% to attain the price of $2.24 on 01/16/2019. Throughout the recent session, the prices were hovering between $2.19 and $2.5271. These shares are 1462.5% off its target price of $35 and the current market capitalization stands at $58.91M. The recent change has given its price a -19.08% deficit over SMA 50 and -95.56% deficit over its 52-week high. The stock witnessed -20.85% declines, -58.52% declines and -69.81% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found INNT’s volatility during a week at 9.17% and during a month it has been found around 9.86%.Innovate Biopharmaceuticals, Inc. (INNT) Top Holders
Institutional investors currently hold around $6 million or 11.4% in INNT stock. Look at its top three institutional owners. Blackrock Inc. owns $2.59 million in Innovate Biopharmaceuticals, Inc., which represents roughly 4.4% of the company’s market cap and approximately 43.2% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 324,315 shares of the stock are valued at $710 thousand. The third largest holder is State Street Corp, which currently holds $579 thousand worth of this stock and that ownership represents nearly 0.98% of its market capitalization.Innovate Biopharmaceuticals, Inc. 13F Filings
At the end of September reporting period, 30 institutional holders increased their position in Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) by some 1,417,262 shares, 9 decreased positions by 1,087,122 and 9 held positions by 450,759. That puts total institutional holdings at 2,955,143 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 296,848 shares while 3 institutional investors sold out their entire positions totaling 995,253 shares.Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) Insider Trades
Multiple company employees have indulged in significant insider trading. Innovate Biopharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Executive Chairman Laumas Sandeep has acquired 3,000 shares of Innovate Biopharmaceuticals, Inc. (INNT) in trading session dated Nov. 30, 2018. These shares are worth $7,890 and were traded at $2.63 each. The SEC filing shows that Proujansky Roy performed a purchase of 1,400 shares. The Director added these shares by way of transaction on Nov. 30, 2018. The company’s shares were assimilated at $2.63 per share worth to an investment of some $3,682 on account of Proujansky Roy.
CEO, Prior Christopher P., purchased 5,000 common shares of Innovate Biopharmaceuticals, Inc. (INNT) in the open market. In a transaction dated Nov. 29, 2018, the shares were bought at an average price of $2.75, giving away a sum of $13,750. After this purchase, 7,009 common shares of INNT are directly owned by the insider, with total stake valued at $15,700.
In the transaction dated Nov. 29, 2018, the great number of shares acquired came courtesy the Executive Chairman; Laumas Sandeep added a total of 3,000 shares at an average price of $2.56, amounting to approximately $7,680. The insider now directly owns 763,373 shares worth $1,709,956.Innovate Biopharmaceuticals, Inc. (INNT) Analyst Guide
Not many analysts have released their opinion on Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.